CO2023015484A2 - Compuesto, composiciones y métodos para el tratamiento de trastornos - Google Patents

Compuesto, composiciones y métodos para el tratamiento de trastornos

Info

Publication number
CO2023015484A2
CO2023015484A2 CONC2023/0015484A CO2023015484A CO2023015484A2 CO 2023015484 A2 CO2023015484 A2 CO 2023015484A2 CO 2023015484 A CO2023015484 A CO 2023015484A CO 2023015484 A2 CO2023015484 A2 CO 2023015484A2
Authority
CO
Colombia
Prior art keywords
methods
compositions
disorders
compound
treatment
Prior art date
Application number
CONC2023/0015484A
Other languages
English (en)
Spanish (es)
Inventor
Rajiah Aldrin Denny
Yingzhi Bi
Ken Carson
Geraldine Cirillo Harriman
Graham A B Hone
Rajiv Gandhi Govindaraj
David J Diller
Original Assignee
Hotspot Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hotspot Therapeutics Inc filed Critical Hotspot Therapeutics Inc
Publication of CO2023015484A2 publication Critical patent/CO2023015484A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CONC2023/0015484A 2021-04-16 2023-11-16 Compuesto, composiciones y métodos para el tratamiento de trastornos CO2023015484A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163175974P 2021-04-16 2021-04-16
US202163281493P 2021-11-19 2021-11-19
PCT/US2022/025083 WO2022221704A1 (en) 2021-04-16 2022-04-15 Compounds, compositions and methods of treating cancer

Publications (1)

Publication Number Publication Date
CO2023015484A2 true CO2023015484A2 (es) 2023-11-30

Family

ID=81580947

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0015484A CO2023015484A2 (es) 2021-04-16 2023-11-16 Compuesto, composiciones y métodos para el tratamiento de trastornos

Country Status (14)

Country Link
US (1) US20240228482A1 (cg-RX-API-DMAC7.html)
EP (1) EP4323358A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024514339A (cg-RX-API-DMAC7.html)
KR (1) KR20240037184A (cg-RX-API-DMAC7.html)
AU (1) AU2022256514A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023021068A2 (cg-RX-API-DMAC7.html)
CA (1) CA3215395A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023003068A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023015484A2 (cg-RX-API-DMAC7.html)
IL (1) IL307732A (cg-RX-API-DMAC7.html)
MX (1) MX2023012245A (cg-RX-API-DMAC7.html)
PE (1) PE20240767A1 (cg-RX-API-DMAC7.html)
TW (1) TW202309023A (cg-RX-API-DMAC7.html)
WO (1) WO2022221704A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4359381A4 (en) * 2021-06-21 2025-04-30 Nimbus Clio, Inc. Cbl-b modulators and uses thereof
US20250042896A1 (en) * 2021-10-29 2025-02-06 Hainan Simcere Zaiming Pharmaceutical Co., Ltd. Polycyclic compound as cbl-b inhibitor
US12187709B2 (en) 2021-11-05 2025-01-07 Genentech, Inc. Lactams as CBL-B inhibitors selective over C-CBL
WO2023205180A1 (en) 2022-04-19 2023-10-26 Nurix Therapeutics, Inc. Biomarkers for cbl, and compositions and methods for their use
WO2023250097A1 (en) 2022-06-22 2023-12-28 Nurix Therapeutics, Inc. Combination therapies with cbl-b inhibitor compounds and antiemetic agents
EP4554586A1 (en) * 2022-07-12 2025-05-21 Hotspot Therapeutics, Inc. Cbl-b inhibitors and anti-pd1/anti-pd-l1 for use in the treatment of cancer
JP2025523682A (ja) * 2022-07-12 2025-07-23 ホットスポット セラピューティクス インコーポレイテッド 複素環式化合物の調製方法
KR20250085707A (ko) * 2022-07-12 2025-06-12 핫스팟 세라퓨틱스, 인크. Cbl-b 조절제로서의 트리아진 유도체의 고체 형태
JP2025523058A (ja) * 2022-07-12 2025-07-17 ホットスポット セラピューティクス インコーポレイテッド Clb-b阻害剤と追加の治療剤を併用した細胞増殖関連病態の処置
WO2024015863A1 (en) * 2022-07-12 2024-01-18 Hotspot Therapeutics, Inc. Cbl-b inhibitor, compositions comprising a cbl-b inhibitor in a method of treating a disease associated with cell proliferation
CN119630662A (zh) * 2022-07-18 2025-03-14 英矽智能科技知识产权有限公司 Cbl-b抑制剂及其应用方法
WO2024077244A1 (en) * 2022-10-07 2024-04-11 Hotspot Therapeutics, Inc. Compounds, compositions and methods of treating disorders
WO2024077236A1 (en) * 2022-10-07 2024-04-11 Hotspot Therapeutics, Inc. Compounds, compositions and methods of treating disorders
WO2024086730A1 (en) * 2022-10-19 2024-04-25 Hotspot Therapeutics, Inc. Heterocyclic cbl-b inhibitors for the treatment of cancer
US20260193251A1 (en) 2022-11-16 2026-07-09 Pfizer Inc. Substituted Bicyclic Pyridone Derivatives
WO2024131939A1 (en) * 2022-12-23 2024-06-27 Insilico Medicine Ip Limited Cbl-b inhibitors and methods of uses thereof
EP4653436A1 (en) * 2023-01-19 2025-11-26 Guangzhou Yufan Nantu Biotechnologies Co., Ltd Heterocyclic compounds, preparation method therefor and use thereof
WO2024153246A1 (zh) * 2023-01-20 2024-07-25 海南先声再明医药股份有限公司 取代的三环化合物及其应用
WO2024227436A1 (en) * 2023-05-04 2024-11-07 InventisBio Co., Ltd. Compounds, preparation methods and uses thereof
WO2025067342A1 (zh) * 2023-09-27 2025-04-03 北京望实智慧科技有限公司 用作Cbl-b抑制剂的化合物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3740837A1 (de) * 1987-11-27 1989-06-08 Schering Ag Substituierte bicyclische triazole, verfahren zu ihrer herstellung und ihre verwendung als herbizide mittel
BRPI0814441A2 (pt) * 2007-07-19 2015-07-14 Schering Corp Compostos de amida heterocíclica como inibidores de proteína cinase
KR20100072266A (ko) * 2007-10-24 2010-06-30 머크 샤프 앤드 돔 코포레이션 헤테로사이클 페닐 아미드 t-형 칼슘 채널 길항제
US10968216B2 (en) * 2016-10-27 2021-04-06 Bayer Aktiengesellschaft 4,5-annulated 1,2,4-triazolones
EP3573971A1 (en) * 2017-01-26 2019-12-04 Araxes Pharma LLC 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
EP3733667B1 (en) * 2017-12-26 2024-06-12 Sumitomo Chemical Company, Limited Heterocyclic compounds and noxious arthropod control agent containing same
KR102922115B1 (ko) * 2019-04-09 2026-02-04 누릭스 테라퓨틱스 인코포레이티드 Cbl-b 억제용의 3-치환된 피페리딘 화합물, 및 암 백신 및/또는 종양용해 바이러스와 조합된 cbl-b 억제제의 용도
CA3294689A1 (en) * 2019-06-26 2026-03-02 Nurix Therapeutics, Inc. Substituted benzyl-triazole compounds for cbl-b inhibition, and further uses thereof
JP2020169215A (ja) * 2020-07-15 2020-10-15 住友化学株式会社 複素環化合物を用いる有害節足動物防除方法
IL301690A (en) * 2020-10-16 2023-05-01 Dana Farber Cancer Inst Inc Piperidinyl small molecule degraders of helios and methods of use
KR20250085707A (ko) * 2022-07-12 2025-06-12 핫스팟 세라퓨틱스, 인크. Cbl-b 조절제로서의 트리아진 유도체의 고체 형태
WO2024015863A1 (en) * 2022-07-12 2024-01-18 Hotspot Therapeutics, Inc. Cbl-b inhibitor, compositions comprising a cbl-b inhibitor in a method of treating a disease associated with cell proliferation
JP2025523682A (ja) * 2022-07-12 2025-07-23 ホットスポット セラピューティクス インコーポレイテッド 複素環式化合物の調製方法
EP4554586A1 (en) * 2022-07-12 2025-05-21 Hotspot Therapeutics, Inc. Cbl-b inhibitors and anti-pd1/anti-pd-l1 for use in the treatment of cancer
JP2025523058A (ja) * 2022-07-12 2025-07-17 ホットスポット セラピューティクス インコーポレイテッド Clb-b阻害剤と追加の治療剤を併用した細胞増殖関連病態の処置

Also Published As

Publication number Publication date
KR20240037184A (ko) 2024-03-21
WO2022221704A1 (en) 2022-10-20
JP2024514339A (ja) 2024-04-01
AU2022256514A1 (en) 2023-10-19
EP4323358A1 (en) 2024-02-21
TW202309023A (zh) 2023-03-01
CA3215395A1 (en) 2022-10-20
MX2023012245A (es) 2024-03-11
PE20240767A1 (es) 2024-04-17
BR112023021068A2 (pt) 2024-01-23
IL307732A (en) 2023-12-01
US20240228482A1 (en) 2024-07-11
CL2023003068A1 (es) 2024-05-03

Similar Documents

Publication Publication Date Title
CL2023003068A1 (es) Compuestos, composiciones y métodos para el tratamiento de trastornos
DOP2022000194A (es) Compuestos de tetralina y tetrahidroquinolina como inhibidores de hif-2alfa
DOP2022000077A (es) Aminas bicíclicas como inhibidoras de la cdk2
MX2024012801A (es) Inhibidores de parp1 de azetidina y pirrolidina y usos de estos
CO2022010330A2 (es) Dosificación de gamma-hidroxibutirato (ghb)
CL2019000221A1 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1.
UY38476A (es) Inhibidores de arg1 y/o arg2
MX2020010469A (es) Inhibidores del atf6 y sus usos.
MX2018016273A (es) Compuestos heterociclicos como inmunomoduladores.
ECSP23057264A (es) Inhibidores de cdk2 y métodos de uso de los mismos
MX2022005563A (es) Ligandos de la pseudoquinasa tyk2.
DOP2018000238A (es) Inhibidores del potenciador del homólogo zeste 2
CL2019002583A1 (es) Inhibidores duales de magl y faah.
CO2022014499A2 (es) Moduladores de nlrp3
MX2024007360A (es) Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas.
MX2021015770A (es) Inhibidores macrociclicos de mcl-1.
MX2020011826A (es) Composiciones de combinacion que comprenden compuestos de bisfluoroalquil-1,4-benzodiazepinona y metodos de uso de las mismas.
CO2024009144A2 (es) Inhibidores de cinasa met
CL2021003442A1 (es) Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer.
MX387726B (es) Derivados de ftalazina como inhibidores de parp1, parp2 y/o tubulina útiles para el tratamiento del cáncer.
CL2023002812A1 (es) Combinaciones farmacéuticas para el tratamiento del cáncer
CL2022003206A1 (es) Compuestos derivados de quinolona y su uso para el tratamiento del cáncer (div. sol. 202102501)
CO2025016192A2 (es) Moléculas y métodos de uso de estas
CL2022002589A1 (es) Tratamiento de trastornos respiratorios
CL2021001944A1 (es) Derivados de aminoácidos para el tratamiento de enfermedades inflamatorias